Ocular Therapeutix (OCUL) Net Equity Issued and Repurchased (2015 - 2024)
Ocular Therapeutix (OCUL) posted quarterly Net Equity Issued and Repurchased of $316.4 million for Q1 2024, up 193.66% on a QoQ basis from $107.7 million in Q4 2023.
Ocular Therapeutix (OCUL) Net Equity Issued and Repurchased (2015 - 2024) Analysis & Trends
Ocular Therapeutix has reported Net Equity Issued and Repurchased for 9 years, with the latest figure at $316.4 million in Q1 2024.
- Net Equity Issued and Repurchased for Q1 2024 came in at $316.4 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2024 was $424.8 million (up 4868.89% YoY), and the FY2023 annual result was $117.3 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased climbed to $316.4 million in Q1 2024, from $107.7 million in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $316.4 million in Q1 2024 and troughed at -$275000.0 in Q1 2021.
- A 4-year average of $76.2 million and a median of $10.8 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
- The widest annual swing landed in 2020, when Net Equity Issued and Repurchased soared 1721.99%; it then sank 102.17% in 2021.
- A 4-year view of Net Equity Issued and Repurchased shows it stood at $162.0 million in 2020, then tumbled by 100.17% to -$275000.0 in 2021, then jumped by 39274.18% to $107.7 million in 2023, then jumped by 193.66% to $316.4 million in 2024.
- Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $316.4 million in Q1 2024, $107.7 million in Q4 2023, and $708000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 316.35 Mn |
| Mar 31, 2024 | 316.35 Mn |
| Dec 31, 2023 | 107.73 Mn |
| Dec 31, 2023 | 107.73 Mn |
| Sep 30, 2023 | 708,000.00 |
| Sep 30, 2023 | 708,000.00 |
| Jun 30, 2023 | 8.82 Mn |
| Jun 30, 2023 | 8.82 Mn |
| Mar 31, 2021 | -275,000.00 |
| Mar 31, 2021 | -275,000.00 |
| Dec 31, 2020 | 161.98 Mn |
| Dec 31, 2020 | 161.98 Mn |
| Jun 30, 2020 | 1.67 Mn |
| Jun 30, 2020 | 1.67 Mn |
| Mar 31, 2020 | 12.69 Mn |
| Mar 31, 2020 | 12.69 Mn |
| Dec 31, 2019 | 8.89 Mn |
| Dec 31, 2019 | 8.89 Mn |
| Sep 30, 2019 | 18.62 Mn |
| Sep 30, 2019 | 18.62 Mn |